April 30, 2014

Devicare announced today the signing of a distribution agreement contract for the Spanish market for Lit-Control products with M4 Pharma Laboratories.

According to Rosendo Garganta, CEO of the company, “the signing of this contract is very important to us because it gives us credibility with the pharmaceutical industry, allowing other international laboratories to become interested in our Renal lithiasis products, but also in our extensive pipeline for other chronic diseases. ”

The agreement with M4 Pharma arrives a month before the National Congress of Urology in 2014 in which both companies will present the Lit-Control products for the preventive treatment of renal lithiasis with hopes to attract the attention of the community of urologists in Spain.

More information:

– Press agreement between Devicare and M4 Pharma.